Group 1 - The stock price of Anjiasi (688581.SH) fell by 4.26% to 68.84 yuan, indicating it is currently in a state of decline since its IPO [1] - Anjiasi was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on May 19, 2023, with an initial offering price of 125.80 yuan per share and a total of 14.47 million shares issued [1] - The total amount raised from the IPO was 182.03 million yuan, with a net amount of 165.10 million yuan after deducting issuance costs, which was 88.03 million yuan more than originally planned [1] Group 2 - The funds raised are intended for projects including the production of 10 million medical endoscope devices, upgrading marketing service networks, and establishing a minimally invasive medical device R&D center [1] - The total issuance costs amounted to 16.93 million yuan, with the lead underwriter, CITIC Securities, receiving 12.89 million yuan in underwriting fees [1] - Strategic placement was conducted by the underwriter, with Zhongzheng Investment subscribing to 3.30% of the shares, amounting to approximately 60 million yuan [2] Group 3 - Anjiasi plans to distribute a cash dividend of 14.5 yuan (including tax) for every 10 shares and issue 4 bonus shares for every 10 shares, with the record date set for June 20, 2024 [2]

Core Viewpoint - The announcement of share reduction plans by shareholders of Anjiasi (688581.SH) indicates a strategic adjustment in their investment positions, with both shareholders planning to reduce their stakes by a total of 1,622,700 shares each, representing 2.0039% of the company's total shares [1][2] Group 1: Shareholder Reduction Plans - Shareholder Suzhou Yuansheng plans to reduce its holdings by up to 1,622,700 shares, with a maximum of 809,700 shares through centralized bidding and 813,000 shares through block trading [1] - Shareholder Hangzhou Tiantang Silicon Valley also plans to reduce its holdings by up to 1,622,700 shares, with the same distribution between centralized bidding and block trading [1] - The reduction period for centralized bidding is 90 natural days starting from 15 trading days after the announcement, while for block trading, it is 90 natural days starting from 3 trading days after the announcement [1] Group 2: Shareholding Structure - As of the announcement date, shareholder Suzhou Yuansheng holds 3,233,835 shares, accounting for 3.9934% of the total shares, with 2,309,882 shares from pre-IPO and 923,953 shares from the 2023 annual bonus shares [2] - Shareholder Hangzhou Tiantang Silicon Valley holds 1,622,700 shares, representing 2.0039% of the total shares, with 1,159,071 shares from pre-IPO and 463,629 shares from the 2023 annual bonus shares [2] - The pre-IPO shares held by these shareholders were released from restrictions and became tradable on May 20, 2024 [2] Group 3: IPO and Fundraising Details - Anjiasi raised a total of 182,032.60 million yuan from its IPO, with a net amount of 165,101.28 million yuan after deducting issuance costs, exceeding the original plan by 88,031.28 million yuan [3] - The funds raised are intended for projects including the production of 10 million medical endoscope devices, marketing network upgrades, and a minimally invasive medical device R&D center [3] - The total issuance costs amounted to 16,931.32 million yuan, with the lead underwriter, CITIC Securities, receiving 12,887.91 million yuan in fees [3] Group 4: Dividend Distribution - Anjiasi announced a cash dividend of 14.5 yuan (including tax) per 10 shares and a distribution of 4 bonus shares per 10 shares for the 2023 fiscal year, with the record date set for June 20 [4]